Cysteine Oxidation within N-terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein*

Huntington disease (HD) is a progressive neurodegenerative disorder caused by expression of polyglutamine-expanded mutant huntingtin protein (mhtt). Most evidence indicates that soluble mhtt species, rather than insoluble aggregates, are the important mediators of HD pathogenesis. However, the differential roles of soluble monomeric and oligomeric mhtt species in HD and the mechanisms of oligomer formation are not yet understood. We have shown previously that copper interacts with and oxidizes the polyglutamine-containing N171 fragment of huntingtin. In this study we report that oxidation-dependent oligomers of huntingtin form spontaneously in cell and mouse HD models. Levels of these species are modulated by copper, hydrogen peroxide, and glutathione. Mutagenesis of all cysteine residues within N171 blocks the formation of these oligomers. In cells, levels of oligomerization-blocked mutant N171 were decreased compared with native N171. We further show that a subset of the oligomerization-blocked form of glutamine-expanded N171 huntingtin is rapidly depleted from the soluble pool compared with “native ” mutant N171. Taken together, our data indicate that huntingtin is subject to specific oxidations that are involved in the formation of stable oligomers and that also delay removal from the soluble pool. These findings show that inhibiting formation of oxidation-dependent huntingtin oligomers, or promoting their dissolution, may have protective effects in HD by decreasing the burden of soluble mutant huntingtin.

[1]  Jeffery N Agar,et al.  Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS , 2010, Nature Neuroscience.

[2]  J. Lucas,et al.  Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. , 2010, Free radical biology & medicine.

[3]  R. Schwarcz,et al.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington’s disease , 2010, Journal of neurochemistry.

[4]  Leslie M Thompson,et al.  Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in Vivo* , 2010, The Journal of Biological Chemistry.

[5]  D. Krainc,et al.  Distinct Region-Specific α-Synuclein Oligomers in A53T Transgenic Mice: Implications for Neurodegeneration , 2010, The Journal of Neuroscience.

[6]  M. Brand,et al.  Rapid turnover of mitochondrial uncoupling protein 3. , 2010, The Biochemical journal.

[7]  S. Finkbeiner,et al.  Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease* , 2010, The Journal of Biological Chemistry.

[8]  S. Finkbeiner,et al.  IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome , 2009, The Journal of cell biology.

[9]  Jeffrey N. Savas,et al.  Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation , 2009, Cell.

[10]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[11]  A. Orr,et al.  Impaired ubiquitin–proteasome system activity in the synapses of Huntington's disease mice , 2008, The Journal of cell biology.

[12]  Keiichiro Suzuki,et al.  Oxidative Modification to Cysteine Sulfonic Acid of Cys111 in Human Copper-Zinc Superoxide Dismutase* , 2007, Journal of Biological Chemistry.

[13]  A. Holmgren,et al.  Oxidation and S-Nitrosylation of Cysteines in Human Cytosolic and Mitochondrial Glutaredoxins , 2007, Journal of Biological Chemistry.

[14]  S. Maeda,et al.  Assembly of two distinct dimers and higher‐order oligomers from full‐length tau , 2007, The European journal of neuroscience.

[15]  S. Hersch,et al.  Mechanisms of Copper Ion Mediated Huntington's Disease Progression , 2007, PloS one.

[16]  W. James,et al.  Oligomerization of the Human Prion Protein Proceeds via a Molten Globule Intermediate* , 2007, Journal of Biological Chemistry.

[17]  K. Mori,et al.  Role of Disulfide Bridges Formed in the Luminal Domain of ATF6 in Sensing Endoplasmic Reticulum Stress , 2006, Molecular and Cellular Biology.

[18]  L. Raymond,et al.  Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.

[19]  Lu Gan,et al.  Palmitoylation of huntingtin by HIP14is essential for its trafficking and function , 2006, Nature Neuroscience.

[20]  W. H. Goldmann,et al.  Huntingtin Associates with Acidic Phospholipids at the Plasma Membrane* , 2005, Journal of Biological Chemistry.

[21]  E. Shoubridge,et al.  Human Sco1 and Sco2 Function as Copper-binding Proteins* , 2005, Journal of Biological Chemistry.

[22]  M. Hayden,et al.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Hyman,et al.  Familial Alzheimer's Disease Presenilin 1 Mutations Cause Alterations in the Conformation of Presenilin and Interactions with Amyloid Precursor Protein , 2005, The Journal of Neuroscience.

[24]  S. Rhee,et al.  Reduction of Cysteine Sulfinic Acid by Sulfiredoxin Is Specific to 2-Cys Peroxiredoxins* , 2005, Journal of Biological Chemistry.

[25]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[26]  S. Hersch,et al.  Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation , 2004, Journal of neurochemistry.

[27]  T. O’Halloran,et al.  Oxygen‐induced maturation of SOD1: a key role for disulfide formation by the copper chaperone CCS , 2004, The EMBO journal.

[28]  W. Fischer,et al.  Protein Disulfide Bond Formation in the Cytoplasm during Oxidative Stress* , 2004, Journal of Biological Chemistry.

[29]  M. Chesselet,et al.  Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.

[30]  Junying Yuan,et al.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders , 2003, Nature.

[31]  C. Ross,et al.  Transglutaminase Cross‐Links in Intranuclear Inclusions in Huntington Disease , 2003, Journal of neuropathology and experimental neurology.

[32]  Sue Goo Rhee,et al.  Inactivation of Human Peroxiredoxin I during Catalysis as the Result of the Oxidation of the Catalytic Site Cysteine to Cysteine-sulfinic Acid* , 2002, The Journal of Biological Chemistry.

[33]  O. Andreassen,et al.  Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease , 2001, Journal of neurochemistry.

[34]  T. O’Halloran,et al.  Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. , 1999, Science.

[35]  M. Beal,et al.  Oxidative Stress in Huntington's Disease , 1999, Brain pathology.

[36]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[37]  J. D. den Dunnen,et al.  Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. , 1996, Human molecular genetics.

[38]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[39]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[40]  M. Ciriolo,et al.  The role of glutathione in copper metabolism and toxicity. , 1989, The Journal of biological chemistry.

[41]  B. Hyman,et al.  Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. , 2010, Biochemical and biophysical research communications.

[42]  H. Lehrach,et al.  Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. , 1999, Methods in enzymology.